Correction of coagulopathy secondary to oral and parenteral anticoagulants

CONTINUUM Lifelong Learning in Neurology

Volumn 15, Issue 3, 2009, Pages 138-157

  Aiyagari, Venkatesh ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; APIXABAN; ARGATROBAN; BETRIXABAN; DABIGATRAN; DALTEPARIN; DANAPAROID; DESULFATOHIRUDIN; EDOXABAN; ENOXAPARIN; FONDAPARINUX; FRESH FROZEN PLASMA; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; NADROPARIN; PHENINDIONE; PHENPROCOUMON; PROTAMINE SULFATE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; RIVAROXABAN; TINZAPARIN; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN; XIMELAGATRAN; YM 150;

ARTICLE; ATAXIA; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CEREBELLUM HEMORRHAGE; CLINICAL FEATURE; CONFUSION; DIZZINESS; DRUG ABSORPTION; DRUG HALF LIFE; DRUG WITHDRAWAL; HEADACHE; HUMAN; INTERNATIONAL NORMALIZED RATIO; NAUSEA; PARTIAL THROMBOPLASTIN TIME; PROGNOSIS; PROTHROMBIN TIME; RISK FACTOR; SUBARACHNOID HEMORRHAGE; THROMBOCYTE; VOMITING;

EID: 77953546060     PISSN: 10802371     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.CON.0000348823.04125.eb     Document Type: Article

References (31)

1. Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 2007;5(suppl 1):60-64.
2. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(6 suppl):160S-198S. (Pubitemid 351892967)
3. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126(3 suppl):204S-233S. (Pubitemid 39297955)
4. Bailey RD, Hart RG, Benavente O, Pearce LA. Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage. Neurology 2001;56(6):773-777.
5. Baker RI, Coughlin PB, Gallus AS, et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004;181(9):492-497.
6. Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 2007;5(suppl 1):60-64.
7. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(6 suppl):160S-198S.
8. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126(3 suppl):204S-233S.
9. Bailey RD, Hart RG, Benavente O, Pearce LA. Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage. Neurology 2001;56(6):773-777.
10. Baker RI, Coughlin PB, Gallus AS, et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004;181(9):492-497.
11. Lin J, Hanigan WC, Tarantino M, Wang J. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg 2003;98(4):737-740.
12. Lind SE, Callas PW, Golden EA, et al. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coagul Fibrinolysis 1997;8(1):48-53.
13. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119(3):480-486.
14. Makris M, Greaves M, Phillips WS, et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997;77(3):477-480.
15. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008;358(20):2127-2137.
16. Pabinger I, Brenner B, Kalina U, et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008;6(4):622-631.
17. Roitberg B, Emechebe-Kennedy O, Amin-Hanjani S, et al. Human recombinant factor VII for emergency reversal of coagulopathy in neurosurgical patients: a retrospective comparative study. Neurosurgery 2005;57(5):832-836; discussion 832-836.
18. Rosand J, Eckman MH, Knudsen KA, et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004;164(8):880-884.
19. Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology 2000;55(7):947-951.
20. Schulman S. Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003;14;349(7):675-683.
21. Schulman S. Optimal reversal of vitamin K antagonists. Thromb Res 2007;119(1):15-16.
22. Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(6 suppl):257S-298S. (Pubitemid 351892969)
23. Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev 2007;21(1):37-48.
24. Siddiq F, Jalil A, McDaniel C, et al. Effectiveness of factor IX complex concentrate in reversing warfarin associated coagulopathy for intracerebral hemorrhage. Neurocrit Care 2008;8(1):36-41.
25. Sjö blom L, Hårdemark HG, Lindgren A, et al. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke 2001;32(11):2567-2574.
26. Sorensen B, Johansen P, Nielsen GL, et al. Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003;14(5):469-477.
27. Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke 2006;37(1):256-262.
28. Watson HG, Baglin T, Laidlaw SL, et al. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001;115(1):145-149.
29. Weitz JI, Hirsh J, Samama MM; American College of Chest Physicians. New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(6 suppl):234S-256S.
30. Yasaka M, Minematsu K, Naritomi H, et al. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost 2003;89(2):278-283.
31. Yasaka M, Sakata T, Naritomi H, Minematsu K. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 2005;115(6):455-459.